SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 30,200 shares, a drop of 12.7% from the August 31st total of 34,600 shares. Based on an average daily volume of 15,700 shares, the short-interest ratio is currently 1.9 days. Approximately 0.4% of the company’s shares are short sold.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. BVF Inc. IL purchased a new position in shares of SAB Biotherapeutics in the 4th quarter valued at about $6,310,000. First PREMIER Bank purchased a new position in SAB Biotherapeutics during the 2nd quarter worth approximately $60,000. RTW Investments LP purchased a new position in SAB Biotherapeutics during the 4th quarter worth approximately $6,310,000. Finally, Commodore Capital LP purchased a new position in SAB Biotherapeutics during the 4th quarter worth approximately $1,259,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Stock Performance

Shares of SABS stock opened at $2.57 on Friday. The firm has a 50 day moving average of $2.73 and a two-hundred day moving average of $3.37. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.24 and a quick ratio of 5.24. SAB Biotherapeutics has a 52 week low of $2.16 and a 52 week high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.34. SAB Biotherapeutics had a negative return on equity of 94.04% and a negative net margin of 1,450.14%. The company had revenue of $0.26 million during the quarter. On average, equities analysts predict that SAB Biotherapeutics will post -3.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

SABS has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, September 9th. Oppenheimer reiterated an “outperform” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Finally, Brookline Capital Management started coverage on SAB Biotherapeutics in a report on Friday, June 7th. They set a “buy” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.75.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.